Reply to “Acute heart failure and interleukin-6: Biomarker, bystander, or therapeutic target?”
Authors:
- 19 August 2026
- journal article
- letter
- Published by Springer Nature in Heart and Vessels
- p. 1-2
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Differential prognostic impact of interleukin-6 in acute heart failure with reduced versus preserved ejection fractionHeart and Vessels, 2026
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseaseNew England Journal of Medicine, 2017
- Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trialEuropean Heart Journal, 2016